AI Article Synopsis
- Most patients with primary CNS lymphoma (PCNSL) relapse after treatment, and there isn't a standard salvage therapy established yet.
- A phase II trial tested the yttrium-90 labeled anti-CD20 antibody ibritumomab tiuxetan on 10 patients with relapsed PCNSL, finding that 4 patients had varying degrees of response, but all experienced significant hematotoxicity.
- The study indicates that while the treatment shows potential for targeting PCNSL, future research should explore combining it with other therapies and autologous stem cell support due to the short response duration and serious side effects.
Article Abstract
Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy. Standard salvage treatment has not yet been established in PCNSL. Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage. The aim of this phase II trial was to evaluate the therapeutic efficacy, toxicity, and biodistribution of yttrium-90 ((90)Y) ibritumomab tiuxetan in PCNSL. Ten patients with relapsed PCNSL were included in a phase II trial and treated with the (90)Y-labeled anti-CD20 antibody ibritumomab tiuxetan. Nine patients actually received the planned radioimmunotherapy. In six patients, biodistribution of the antibody was measured by indium-111 ((111)In) ibritumomab tiuxetan whole-body scans and single-photon-emission CT (SPECT) of the brain. All patients were evaluated for toxicity and response at least 4 weeks after therapy. Four patients responded: one patient had a complete response lasting 30+ months, and three patients had short-lived responses of
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743222 | PMC |
| http://dx.doi.org/10.1215/15228517-2008-108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma.
Explor Target Antitumor Ther
February 2024
Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.
Article Synopsis
- * Two RIT agents, Zevalin and Bexxar, have been approved by the FDA for treating specific types of NHL, but their use has declined due to the rise of new therapies and complexities in administering them.
- * New advancements in RIT include novel targets, therapeutic strategies using alpha-particle isotopes for better tumor targeting, and the development of immuno-PET imaging for personalized treatment monitoring.
A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
Oncologist
April 2024
Division of Hematology and Oncology, University of Arizona School of Medicine, Tucson, AZ, USA.
Article Synopsis
- The study reviews the clinical efficacy and safety of anti-CD20 radioimmunotherapy (RIT) for treating indolent B-cell lymphomas, highlighting two approved agents: 90Y-ibritumomab tiuxetan and 131I-tositumomab.
- Numerous clinical trials support RIT's effectiveness, especially in high-risk and heavily pretreated patient populations, with manageable toxicity profiles.
- Continued research is needed to explore long-term response biomarkers and optimize RIT within treatment strategies, as it shows promise for sustained remission and serves as a viable alternative to other therapies.
The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.
Leuk Lymphoma
March 2024
Division of Hematology, Department of Medicine, Mayo Clinic Rochester, MN, USA.
Patients with asymptomatic follicular lymphoma (AFL) are candidates for observation or immunotherapy. Given the effectiveness of radiation therapy in FL, another option is 90Yttrium-ibritumomab tiuxetan radioimmunotherapy (RIT). We conducted a trial where untreated AFL patients were randomized to rituximab 375 mg/m2 weekly × 4 or rituximab 250 mg/m days 1, 8, and 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!